Articles related to VITAMINS/SUPPLEMENTS

In a synopsis from ACTRIMS San Diego forum at the end of February, most patients who achieved a “no evidence of disease activity” in the first 6 months of therapy with Briumvi continued to show no active disease at the 2-year mark. At the same time, high-dose vitamin D appears to have no effect in controlling MS. And a suspension of gold nanoparticles designed to increase intracellular energy production, and previously demonstrating positive effects on cognition, vision, and motor function in MS, is the focus of a new study set to begin enrolling patients with progressive forms of MS.

Sibutramine, a serotonin, norepinephrine, and dopamine reuptake inhibitor, can cause an increase in heart rate and blood pressure that may place individuals with cardiovascular disease at risk.

The results of these trials show that vitamin D reduced the risk of diabetes progression by 3% to 18% after three years, with serum 25-hydroxy D levels of at least 125 nmol/L showing the greatest benefit. Vitamin D was also associated with a 30% increase in the likelihood of returning to normal glucose regulation.

This summary of a January 2023 JACC article highlights the study finding that rosuvastatin was “vastly superior to… any of the six supplements studied in the trial.” The study compared rosuvastatin to cinnamon, garlic, turmeric, red yeast rice, fish oil, and plant sterols. Rosuvastatin yielded a reduction in cholesterol of nearly 38 percent in just 28 days. The supplements had little to no effect but were significantly more costly than the statin.

If eponyms are avoided, Wernicke encephalopathy, commonly known as Wernicke-Korsakoff syndrome or alcoholic encephalopathy, is a kind of thiamine (vitamin B1) deficiency that is frequently observed in alcoholics. Imaging typically reveals mamillary bodies, dorsomedial thalami, tectal plate, periaqueductal area, and/or the area around the third ventricle as areas of symmetrical enhanced T2/FLAIR signal.

The only effective ways to treat TEC are to stop, delay, or modify your patients’ chemotherapy dose. Supportive medications, such as topical keratolytics, wound care, and high-potency topical corticosteroids, respond differently. These medications cause a 2- to 4-week recovery period following the interruption of chemotherapy, which is a somewhat gradual improvement.